The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than 700 world-class investment firms that we track and now have access to the collective wisdom contained in […]
VANCOUVER , May 7, 2020 /CNW/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced that it will host an Analyst & Investor Call to discuss anemia and transfusion dependency, two critical unmet medical needs in treating patients with myelofibrosis, on Wednesday, May 13 th at 10:00 am ET . The event will feature a presentation by renowned myelofibrosis expert Dr. Ruben Mesa , Director of the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center. "Cytopenias are very common in myelofibrosis, with anemia and the resulting transfusion dependency being strongly associated with poor prognosis and impaired survival in this disease," said Dr. Mesa.
Company also exceeds offering target Continue reading...
VANCOUVER , Feb. 26, 2020 /CNW/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced that its financial results for 2019 will be released on Tuesday, March 3 prior to market open. The management team from Sierra, at 8:00 a.m. ET , will host a conference call to discuss the company's progress made in 2019 and its plans for 2020. Call registration is available through the Sierra Oncology website at www.sierraoncology.com.
Sierra Oncology has been struggling lately, but the selling pressure may be coming to an end soon.
Sierra Oncology (SRRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings.
Sierra Oncology, Inc. (Nasdaq: SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced that it will host an Analyst & Investor Event on Sunday, December 8th at 7:00 am ET to discuss newly reported clinical data for momelotinib that will be presented at the 61st American Society of Hematology (ASH) Annual Meeting in Orlando, Florida.
Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced that Dose Intensity and Long-Term Safety data for momelotinib will be presented in two posters at the 25th European Hematology Association (EHA) Virtual Congress taking place from June 11-21, 2020.
Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced that its board of directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-40. The reverse stock split will be effective today at 4:30 p.m. Eastern Time. At the market open on January 23, 2020, the Company's common stock will continue to trade on The Nasdaq Global Market under the symbol "SRRA," but will be assigned a new CUSIP number (82640U404) and will trade on a split-adjusted basis.
VANCOUVER , May 27, 2020 /CNW/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced that Dr. Barbara Klencke , Chief Development Officer, will present the company at the upcoming Jefferies Global Virtual Healthcare Conference and at the Oppenheimer Biotech by the Lake 2020 Investor Summit. Sierra Oncology is a late stage drug development company focused on achieving the successful registration and commercialization of momelotinib, a potent, selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor with a targeted mechanism of action that enables it to address all three key drivers of myelofibrosis.
Sierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Sierra Oncology Reports 2019 Year End Results
VANCOUVER , May 26, 2020 /CNW/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced the appointment of Dr. Stephen Dilly as President and Chief Executive Officer, effective June 1, 2020 . In addition, Dr. Dilly and Mr. Craig Collard have been appointed to the company's Board of Directors.
VANCOUVER , Feb. 6, 2020 /CNW/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced that the Series A convertible voting preferred stock issued in its recently completed $103.0 million financing (gross proceeds) have been fully converted into shares of common stock. In addition, Gilead Sciences, Inc. (Gilead) has been issued 725,283 shares of common stock and a warrant to purchase an equivalent amount of common stock, in consideration for meaningfully reduced royalty rates and elimination of a near term milestone in an amendment to the Asset Purchase Agreement with Gilead for momelotinib, as previously announced.
More companies to consider for the new year that are trading at a discount to net-net working capital Continue reading...
Sierra Oncology Reports First Quarter 2020 Results
Sierra Oncology, Inc. (Nasdaq: SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced that it has closed its previously announced underwritten public offering, with gross proceeds to Sierra Oncology of $103 million.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 10) AbbVie Inc (NYSE: ABBV ) Allergan plc (NYSE: AGN ) ...
Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced that Dr. Nick Glover, President and Chief Executive Officer, will present an overview of the company entitled "Building MOMENTUM for Patients with Myelofibrosis" at the Cowen 40th Annual Health Care Conference in Boston, Massachusetts.